💪Testosterone & Hormonal Support

The endogenous hypothalamic decapeptide that controls reproductive hormone release, used clinically for fertility treatment and diagnostics, and in TRT protocols to maintain testicular function.

A synthetic GnRH agonist that, through continuous administration, paradoxically suppresses gonadotropin secretion and sex hormone production, used for prostate cancer, endometriosis, precocious puberty, and uterine fibroids.

The pharmaceutical-grade form of Thymosin Alpha-1, FDA-approved in over 30 countries for hepatitis B/C and as an immune modulator for cancer therapy.

A synthetic GnRH agonist decapeptide used medically for prostate cancer, endometriosis, and off-label for PCT (post-cycle therapy) to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use.

A 10-amino acid fragment of kisspeptin that is the most potent endogenous stimulator of GnRH release, playing a critical role in reproductive hormone regulation and fertility.

A mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, protecting cardiolipin and restoring bioenergetics in aging and disease.

A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.

A PEGylated growth hormone receptor antagonist that blocks GH action at the receptor level, used to treat acromegaly by normalizing IGF-1 levels without reducing GH secretion.

An FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification, indicated for HIV-associated lipodystrophy and studied for cognitive benefits and visceral fat reduction.

A synthetic octapeptide analog of somatostatin with prolonged activity, used to treat acromegaly, carcinoid tumors, and vasoactive intestinal peptide-secreting tumors.

A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor (GHS-R1a), notable for its potent GH-releasing effects and strong appetite stimulation.

A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full-length HGH.

A synthetic analog of vasopressin (antidiuretic hormone) that is one of the most widely prescribed peptide drugs worldwide. Used for diabetes insipidus, bedwetting, and bleeding disorders.

An investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis) with significant liver fat reduction.

A D-retro-inverso peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, representing a targeted senolytic approach to aging.

A long-acting synthetic somatostatin analog administered as a deep subcutaneous depot injection every 4 weeks for acromegaly and neuroendocrine tumors.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management, with cardiovascular and neuroprotective benefits.

An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, producing unprecedented weight loss of up to 24% in clinical trials.

An mTOR inhibitor gaining popularity in longevity research for its ability to slow aging, enhance autophagy, and extend lifespan in multiple species.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with proven cardiovascular benefits and convenient single-use pen delivery.

A 28-amino acid thymic peptide that modulates immune function, approved in multiple countries for hepatitis B and used as an immune enhancer in cancer and infectious disease.

A mitochondria-derived 24-amino acid peptide with potent cytoprotective and neuroprotective effects, being studied for Alzheimer's disease, metabolic health, and longevity.

A popular clinical combination of two growth hormone secretagogues that work through complementary pathways — GHRH receptor (sermorelin) and ghrelin receptor (ipamorelin) — for synergistic GH release with minimal side effects.

A synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that induces skin tanning, increases libido, and reduces appetite through melanocortin receptor activation.

A synthetic hexapeptide growth hormone secretagogue considered to offer the best balance of potency and side effect profile among the GHRP family.

A synthetic hexapeptide growth hormone secretagogue that potently stimulates GH release through the ghrelin receptor, with additional cardioprotective properties.

The first GLP-1 receptor agonist approved for type 2 diabetes, originally derived from Gila monster venom, available in twice-daily and once-weekly formulations.

A 9-amino acid endogenous peptide hormone produced in the hypothalamus that regulates water retention, blood pressure, and social behavior through V1 and V2 receptor activation.

An FDA-approved melanocortin receptor agonist that treats hypoactive sexual desire disorder (HSDD) in premenopausal women by acting directly on the central nervous system to increase sexual desire and arousal.

A long-acting amylin receptor agonist in clinical development for obesity, designed for weekly subcutaneous injection and being studied in combination with semaglutide (CagriSema) for enhanced weight loss.